- recruitingPHASE2
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
This study is looking into a new medication called NEU-411 for people aged 40-80 with early Parkinson's disease. It focuses on those with a specific genetic marker. The aim is to see if the drug is safe and effective in slowing the disease's progress.
United States · Israel · Italy - authorisedTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study and Open-Label Extension to Evaluate the Safety and Efficacy of NEU-411 in Companion Diagnostic-Positive Participants with Early Parkinson’s Disease (NEULARK)
This study is testing a new medicine, NEU-411, for people recently diagnosed with Parkinson's disease. Researchers want to see if it's safe and helps with symptoms, using a special app to measure changes over about a year.
Spain · Poland · Italy